Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · NovoCure Ltd (NVCR)

Novocure gets FDA Not Approvable Letter for Optune Mya in lung cancer brain metastases

Negative Impact 4 of 5 legal/regulatory

Novocure said it received a Not Approvable Letter from the U.S. Food and Drug Administration for its Premarket Approval application for Optune Mya, which treats adult patients with brain metastases from non-small cell lung cancer after stereotactic radiation. The FDA said uncertainty about the degree of clinical benefit prevented approval, and the company said it has no assurance that further discussions or submissions will lead to approval.

Key points

  • The FDA's Not Approvable Letter cites uncertainty around the degree of clinical benefit provided by Optune Mya.
  • The FDA did not raise concerns about the device's safety profile.
  • Novocure plans to meet with the FDA to see whether any options could support approval without additional clinical studies.
  • The filing gives no timeline for those discussions and no assurance of approval.

The filing

CompanyNovoCure Ltd (NVCR)
Form8-K, current report
Filed with the SECNov 9, 2026, 6:59 AM ET
Accession number0001645113-26-000085

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.